| abstract |
This application relates to (E)-methyl 6-((3S,8S,9S,10R,13S,14S,17R)-3-(((5S,6R)-5-acetoxy-6-(acetoxy Methyl)-5,6-dihydro-2H-pyran-2-yl)oxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12, Crystalline form of 13,14,15,16,17-tetradecahydro-1H-cyclopentadiene[a]phenanthrene-17-yl)hept-5-enoate, and vascular leakage resistance comprising the same retardation agent. The new crystal form has high purity, excellent stability, excellent long-term storage and drug stability, and can be used as a vascular leakage blocker, so it is very advantageous in the production of high-quality drugs. |